Efficacy and safety of natalizumab Extended Interval Dose (EID) and Standard Interval Dose (SID) in patients with relapsing-remitting mltiple-sclerosis : Italian cohort experience
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2016
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 16 Nov 2016 New trial record.